CIBC World Keeps 'Buy' on ImClone
Analyst Matthew Geller says the revised drug development deal with Bristol Myers is a strong positive for the company
CIBC World reiterates buy on ImClone (IMCL )/.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.